Testing effectiveness (Phase 2)Study completedNCT02834364
What this trial is testing
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Who this might be right for
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical Center 12